Other News To Note
Wednesday, September 28, 2011
Talon Therapeutics Inc., of San Mateo, Calif., reported that its new drug application for Marqibo (vincristine sulfate liposomes injection) has been accepted for filing by the FDA under accelerated approval. Prior to the May PDUFA date, Talon plans to begin enrollment in a Phase III confirmatory trial of Marqibo for the treatment of adults, 60 or older, with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.